Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fluorine-18 psma-1007
- Development stage
- Unknown
- Lead developer
- ABX
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
NMK02 is a fluorine-18 labeled radiopharmaceutical diagnostic imaging agent developed by Nihon Medi-Physics for the detection and staging of prostate cancer. It consists of the small molecule ligand PSMA-1007, which has high affinity for the prostate-specific membrane antigen (PSMA), a cell-surface protein significantly overexpressed in prostate adenocarcinoma. Upon intravenous administration, NMK02 binds to PSMA-expressing cells, allowing for high-resolution visualization of primary tumors and metastatic lesions via positron emission tomography (PET). A distinguishing feature of NMK02 (PSMA-1007) is its predominantly hepatobiliary excretion, which minimizes urinary tract interference and potentially improves the detection of local recurrences in the prostate bed compared to other PSMA-targeted tracers. The agent was licensed by Nihon Medi-Physics from ABX GmbH for development in the Japanese market.
- Other names
- [18F]PSMA-100718F-PSMA-1007fluorine-18-labeled PSMA-1007fluorine18-labeled PSMA-1007fluorine 18-labeled PSMA-1007
02
Targets
PSMA (Prostate-specific membrane antigen)
Beyond the preview
Go deeper on fluorine-18 psma-1007.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fluorine-18 psma-1007.